Search

Displaying results 2631 - 2640 of 10000 in total
  1. Indication

    Metastatic Non-Small Cell Lung Carcinoma (NSCLC)

    go.drugbank.com/conditions/DBCOND0145710
    Drugs: Nintedanib
    Synonyms: Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
  2. Indication

    Microinvasive endobrachial Non-Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0022194
    Drugs: Porfimer sodium
    Synonyms: Microinvasive endobrachial Non-Small Cell Lung Cancer
  3. Indication

    Partially obstructive Non-Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0022198
    Drugs: Porfimer sodium
    Synonyms: Partially obstructive Non-Small Cell Lung Cancer
  4. Indication

    Refractory, metastatic Non small cell lung cancer

    go.drugbank.com/conditions/DBCOND0025490
    Drugs: Ceritinib · Docetaxel
    Synonyms: Refractory, metastatic non small-cell lung cancer, Refractory, metastatic Non-small cell lung cancer
  5. Indication

    Relapsed Diffuse large B-cell lymphoma NOS

    go.drugbank.com/conditions/DBCOND0103396
    Drugs: Loncastuximab tesirine · Polatuzumab vedotin · Selinexor · Tafasitamab
    Synonyms: Relapsed Diffuse large B-cell lymphoma NOS
  6. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. … [A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.

  7. Drug

    Candida albicans

    go.drugbank.com/drugs/DB10429
    ApprovedInvestigational

    Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.

    Mixtures: New Stock Fungi Mix, New Stock Fungi MixCategories: Non-Standardized Fungal Allergenic Extract
  8. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.

  9. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah.

  10. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.